137 related articles for article (PubMed ID: 27248988)
21. W1, a Novel Oral Antiplatelet Agent With Less Resistance Than Clopidogrel.
Ge P; Du L; Han C; Li H; Feng Y; Han J; Wang Z; Xiong L; Yuan M; Liu Y
J Cardiovasc Pharmacol; 2017 Feb; 69(2):110-117. PubMed ID: 27930430
[TBL] [Abstract][Full Text] [Related]
22. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
[TBL] [Abstract][Full Text] [Related]
23. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
[TBL] [Abstract][Full Text] [Related]
24. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
25. [Absorption dynamic characteristics of clopidogrel bisulfate polymorphs in rat].
Yu XY; Chen QX; Bai XY; Tian S; Sun JL; Lü Y; Du GH
Yao Xue Xue Bao; 2011 Oct; 46(10):1268-72. PubMed ID: 22242463
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of the alkylated active metabolite of tipidogrel.
Zhi S; Xia G; Liu Y; Tao Z; Chen L; Liu D
Bioorg Med Chem Lett; 2015 Apr; 25(8):1718-1723. PubMed ID: 25801935
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics, mass balance, and metabolism of [
Zheng YD; Zhang H; Zhan Y; Bian YC; Ma S; Gan HX; Lai XJ; Liu YQ; Gong YC; Liu XF; Sun HB; Li YG; Zhong DF; Miao LY; Diao XX
Acta Pharmacol Sin; 2021 Sep; 42(9):1535-1546. PubMed ID: 33244163
[TBL] [Abstract][Full Text] [Related]
28. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.
Hagihara K; Kazui M; Kurihara A; Yoshiike M; Honda K; Okazaki O; Farid NA; Ikeda T
Drug Metab Dispos; 2009 Nov; 37(11):2145-52. PubMed ID: 19704027
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs.
Brainard BM; Kleine SA; Papich MG; Budsberg SC
Am J Vet Res; 2010 Jul; 71(7):822-30. PubMed ID: 20594086
[TBL] [Abstract][Full Text] [Related]
30. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel.
Savi P; Herbert JM; Pflieger AM; Dol F; Delebassee D; Combalbert J; Defreyn G; Maffrand JP
Biochem Pharmacol; 1992 Aug; 44(3):527-32. PubMed ID: 1510701
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of Biologically Active Piperidine Metabolites of Clopidogrel: Determination of Structure and Analyte Development.
Shaw SA; Balasubramanian B; Bonacorsi S; Cortes JC; Cao K; Chen BC; Dai J; Decicco C; Goswami A; Guo Z; Hanson R; Humphreys WG; Lam PY; Li W; Mathur A; Maxwell BD; Michaudel Q; Peng L; Pudzianowski A; Qiu F; Su S; Sun D; Tymiak AA; Vokits BP; Wang B; Wexler R; Wu DR; Zhang Y; Zhao R; Baran PS
J Org Chem; 2015 Jul; 80(14):7019-32. PubMed ID: 26151079
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and inhibition of platelet aggregation for some 1-o-chlorophenyl-1,2,3,4-tetrahydroisoquinoline derivatives.
Yang J; Hua WY; Wang FX; Wang ZY; Wang X
Bioorg Med Chem; 2004 Dec; 12(24):6547-57. PubMed ID: 15556771
[TBL] [Abstract][Full Text] [Related]
33. Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro.
Abell LM; Liu EC
J Pharmacol Exp Ther; 2011 Nov; 339(2):589-96. PubMed ID: 21828263
[TBL] [Abstract][Full Text] [Related]
34. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
Farid NA; Small DS; Payne CD; Jakubowski JA; Brandt JT; Li YG; Ernest CS; Salazar DE; Konkoy CS; Winters KJ
Pharmacotherapy; 2008 Dec; 28(12):1483-94. PubMed ID: 19025429
[TBL] [Abstract][Full Text] [Related]
35. Identification and biological activity of the active metabolite of clopidogrel.
Savi P; Pereillo JM; Uzabiaga MF; Combalbert J; Picard C; Maffrand JP; Pascal M; Herbert JM
Thromb Haemost; 2000 Nov; 84(5):891-6. PubMed ID: 11127873
[TBL] [Abstract][Full Text] [Related]
36. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
[TBL] [Abstract][Full Text] [Related]
37. 2-chlorophenyl zinc bromide: a convenient nucleophile for the mannich-related multicomponent synthesis of clopidogrel and ticlopidine.
Aillaud I; Haurena C; Gall EL; Martens T; Ricci G
Molecules; 2010 Nov; 15(11):8144-55. PubMed ID: 21072025
[TBL] [Abstract][Full Text] [Related]
38. Calcium-Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel.
Gremmel T; Durstberger M; Eichelberger B; Koppensteiner R; Panzer S
Cardiovasc Ther; 2015 Oct; 33(5):264-9. PubMed ID: 26014752
[TBL] [Abstract][Full Text] [Related]
39. Very slow chiral inversion of clopidogrel in rats: a pharmacokinetic and mechanistic investigation.
Reist M; Roy-de Vos M; Montseny JP; Mayer JM; Carrupt PA; Berger Y; Testa B
Drug Metab Dispos; 2000 Dec; 28(12):1405-10. PubMed ID: 11095576
[TBL] [Abstract][Full Text] [Related]
40. CYP-independent inhibition of platelet aggregation in rabbits by a mixed disulfide conjugate of clopidogrel.
Zhang H; Lauver DA; Hollenberg PF
Thromb Haemost; 2014 Dec; 112(6):1304-11. PubMed ID: 25230737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
